Scientific Programme

The 30th Annual Meeting Scientific Committee established an inspiring programme* on the topic "Progressive MS from pathology to treatment".

* Changes to the programme may apply.

Hour
Location
Title Location
10:00 - 11:00
Satellite Symposium
11:15 - 12:15
Satellite Symposium
12:15 - 13:30
Light Lunch & Poster Viewing
13:30 - 13:35
Opening
13:35 - 13:45
Introduction
Giancarlo Comi
13:45 - 14:15
XXX ECF Lecture
Alan Thompson
14:15 - 15:45
Session I - Pathology
Tanja Kuhlmann
14:15 - 14:35 What defines progression in pathology
Hans Lassmann
 
14:35 - 14:55 Role of cortical lesions
Roberta Magliozzi
 
14:55 - 15:15 Axonal and synaptic pathology and failure of repair
Christine Stadelmann
 
15:15 - 15:35 Slowly expanding lesions
Stephan Bramow
 
15:35 - 15:45 Q & A
 
15:45 - 17:45
Session II - Mechanistic aspects
Ariel Miller
15:45 - 16:05 Energy failure
Don J. Mahad
 
16:05 - 16:25 Role of acquired and innate immunity
Wee Yong
 
16:25 - 16:45 Immunosenescence
Heinz Wiendl
 
16:45 - 17:05 What determines the efficiency of remyelination?
Robin Franklin
 
17:05 - 17:15 Q & A
 
17:15 - 18:15
Coffee Break & Poster Viewing
18:15 - 19:15
Satellite Symposium
19:15 - 20:00
Scientific Networking Cocktail
Hour
Location
Title Location
07:30 - 08:30
Satellite Symposium
08:30 - 10:00
Session III - Contribution of epidemiology to understanding progression
Maria Trojano
08:30 - 08:50 Risk factors for secondary progressive MS
Jan Hillert
 
08:50 - 09:10 Prognostic factors in progressive MS (including aging and comorbidities)
Mar Tintoré
 
09:10 - 09:30 PIRA and silent progression
Ludwig Kappos
 
09:30 - 09:50 Do we need a revision of the classification of MS courses
Fred Lublin
 
09:50 - 10:00 Q & A
 
10:00 - 10:30
Coffee Break & Poster Viewing
10:30 - 12:00
Session IV - Biomarkers
Hans-Peter Hartung
10:30 - 10:50 MRI
Douglas L. Arnold
 
10:50 - 11:10 PET
Bruno Stankoff
 
11:10 - 11:30 Body fluid biomarkers in progressive MS: NfL and beyond
Jens Kuhle
 
11:30 - 11:50 Functional biomarkers (including wearable devices)
Letizia Leocani
 
11:50 - 12:00 Q & A
 
12:00 - 13:00
Satellite Symposium
13:00 - 14:00
Light Lunch
14:00 - 15:30
Session V - Clinical trials designs and outcomes
Bernard M.J. Uitdehaag
14:00 - 14:20 Early phase trials: exploring efficacy and disease biology
Marco Salvetti
 
14:20 - 14:40 Phase III RCTs
Robert Fox
 
14:40 - 15:00 Phase II and III RCTs for remyelination
Catherine Lubetzki
 
15:00 - 15:20 Large studies interventions
Jeremy Chataway
 
15:20 - 15:30 Q & A
 
15:30 - 17:00
Session VI - Treatment of PMS today
Gilles Edan
15:30 - 15:50 Approved MS DMTs
Xavier Montalban
 
15:50 - 16:10 Physical rehabilitation
Peter Feys
 
16:10 - 16:30 Cognitive rehabilitation
Maria Pia Amato
 
16:30 - 16:50 Future perspectives in symptomatic treatments
Oscar Fernández
 
16:50 - 17:00 Q & A
 
17:00 - 17:20
Coffee Break
17:20 - 17:30
Announcement Young Investigator Award Winners
17:30 - 18:00
Actrims Lecture
18:15 - 19:15
Satellite Symposium
Hour
Location
Title Location
07:30 - 08:15
Satellite Symposium
08:30 - 10:00
Session VII - Future treatments: possible targets
Prof Per Soelberg Sørensen
08:30 - 08:50 Axonal degeneration
Prof Dr Gavin Giovannoni
 
08:50 - 09:10 Expanding lesions
Prof Dr Daniel Reich
 
09:10 - 09:30 Astrocytes and microglia
Francisco Javier Quitana
 
09:30 - 09:50 Remyelination
Hans-Peter Hartung
 
09:50 - 10:00 Q & A
 
10:00 - 10:30
Coffee Break
10:30 - 11:00
Young Investigator Awards
11:00 - 12:30
Session VIII - Raising the bar to stop progression: a global approach
Paola Zaratin
11:00 - 11:20 PROMS
Prof Dr Patrick Vermersch
 
11:20 - 11:40 PMSA
Robert Fox
 
11:40 - 12:00 Role of industry
Robert Hyde
 
12:00 - 12:20 Regulatory agencies
Elena Hernandez Martinez De Lapiscina
 
12:20 - 12:30 Q & A
 
12:30 - 13:00
Concluding Remarks
Giancarlo Comi
13:00 - 14:00
Lunch